SHMT2

Across TCGA pan-cancer cohorts, SHMT2 RNA differs between tumor and matched normal tissue in 16 of 18 cancer types tested, making tumor–normal expression one of SHMT2’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where SHMT2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types SHMT2 is over-expressed in tumor.

KIRC, COAD, and BLCA are the cancer types where SHMT2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SHMT2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Female	III,IV	+2.357	<.001	12	view →
COAD	Male	IV	+2.020	<.001	12	view →
BLCA	Male	IV	+1.924	<.001	11	view →
KIRP	Female	II,III,IV	+1.531	<.001	11	view →
HNSC	Male	All	+1.250	<.001	11	view →
THCA	Female	III,IV	+0.723	<.001	10	view →
LUAD	Male	III,IV	+1.511	<.001	9	view →
STAD	Male	II,III,IV	+1.445	<.001	9	view →
LUSC	Female	All	+2.024	<.001	8	view →
READ	All	All	+1.299	<.001	7	view →
UCEC	All	III,IV	+1.815	<.001	6	view →
BRCA	All	III,IV	+0.920	<.001	6	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 16 lineages.

SHMT2–KIRC

Open the KIRC breakdown →